



The Drug Utilization Review Board Reviewed the Following New Drugs and Supplemental Rebate Classes on September 19, 2013

The Georgia Medicaid Fee-for-Service Drug Utilization Review (DUR) Board has conducted its clinical and financial evaluations and provided its recommendations for the Department of Community Health's (DCH) final decisions on the following new drugs and therapeutic classes for the Georgia Medicaid Fee-for-Service Preferred Drug List (PDL).

New Drug Reviews

Anticoagulant

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Eliquis*[®] (Oral) Tablet. The DUR Board also recommended *Preferred* status for *Coumadin*[®] (Oral) Tablet.

Short Bowel Syndrome

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Gattex*[®] (Subcutaneous) Kit.

Antihyperlipidemics for Homozygous Familial Hypercholesterolemia

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Juxtapid*[™] (Oral) Capsule and *Kynamro*[®] (Subcutaneous) Syringe.

Urea Cycle Disorder

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Ravicti*[®] (Oral) Liquid.

Antihyperlipidemic for Hypertriglyceridemia

The DUR Board recommended *Non-Preferred* status with *Prior Authorization* for *Vascepa*[®] (Oral) Capsule.

Therapeutic Class Reviews

The following classes were reviewed with recommendations for changes in PDL status for the following drugs.

Analgesics, Opioid Abuse, Buprenorphine-Naloxone Agents

The DUR Board recommended *Preferred* status with *Prior Authorization* for *Zubsolv*[®] (Sublingual) Tablet.

Antivirals, Influenza Agents

The DUR Board recommended *Non-Preferred* status for *Rimantadine* (Oral) Tablet.